$2.05
5.13% yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$2.05
+0.33 19.19% 1M
-2.03 49.69% 6M
+0.22 12.02% YTD
-10.74 83.97% 1Y
-20.63 90.96% 3Y
-167.99 98.79% 5Y
-95.27 97.89% 10Y
Nasdaq, Closing price Fri, May 16 2025
+0.10 5.13%
ISIN
US45773H2013
Symbol
INO
Sector

Key metrics

Market capitalization $71.52m
Enterprise Value $14.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 51.54
P/S ratio (TTM) P/S ratio 255.43
P/B ratio (TTM) P/B ratio 1.40
Revenue growth (TTM) Revenue growth -60.52%
Revenue (TTM) Revenue $280.00k
EBIT (operating result TTM) EBIT $-105.96m
Free Cash Flow (TTM) Free Cash Flow $-102.70m
Cash position $68.36m
EPS (TTM) EPS $-3.19
P/E forward negative
P/S forward 703.47
EV/Sales forward 141.93
Short interest 17.75%
Show more

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Inovio Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.28 0.28
61% 61%
100%
- Direct Costs 3.11 3.11
0% 0%
1,111%
-2.83 -2.83
18% 18%
-1,011%
- Selling and Administrative Expenses 30 30
21% 21%
10,700%
- Research and Development Expense 70 70
9% 9%
25,021%
-103 -103
13% 13%
-36,732%
- Depreciation and Amortization 3.11 3.11
0% 0%
1,111%
EBIT (Operating Income) EBIT -106 -106
12% 12%
-37,844%
Net Profit -96 -96
23% 23%
-34,457%

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Roger Song - Jefferies Yi ...
Neutral
PRNewsWire
3 days ago
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25 Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Comm...
Neutral
Seeking Alpha
7 days ago
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference.
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jacqueline Shea
Employees 134
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today